Registration Dossier

Diss Factsheets

Administrative data

Description of key information

Key value for chemical safety assessment

Skin sensitisation

Link to relevant study records
Reference
Endpoint:
skin sensitisation: in vivo (non-LLNA)
Type of information:
experimental study
Adequacy of study:
key study
Study period:
from 1993-09-09 to 1994-01-14
Reliability:
1 (reliable without restriction)
Rationale for reliability incl. deficiencies:
other: GLP, OCDE guideline 406 (1981 May the 12th)
Qualifier:
according to guideline
Guideline:
OECD Guideline 406 (Skin Sensitisation)
Deviations:
no
GLP compliance:
yes
Type of study:
guinea pig maximisation test
Species:
guinea pig
Strain:
Dunkin-Hartley
Sex:
male/female
Details on test animals and environmental conditions:
TEST ANIMALS
- Source: Centre d'élevage Lebeau, 78950 Gambais, France
- Age at study initiation: no data
- Weight at study initiation: 399+/-28g (Males), 391+/-39g (Females)
- Housing: individually
- Diet (e.g. ad libitum): ad libitum "Guinea pig sustenance reference 106 diet" (U.A.R., 91360 Villmoisson-sur-Orge, France)
- Water (e.g. ad libitum): drinking water filtered by a F.G. Milliporemembrane 0,22µ)
- Acclimation period: at least 5 days before the beginning of the study


ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22+/-3°C
- Humidity (%): 50+/-20%
- Air changes (per hr): no data
- Photoperiod (hrs dark / hrs light): 12/12


IN-LIFE DATES: From: To: 1993-10-08
Route:
intradermal and epicutaneous
Vehicle:
physiological saline
Concentration / amount:
intradermal induction phase: 1%
cutaneous induction phase: 25%
challenge phase: 10%
Route:
epicutaneous, occlusive
Vehicle:
physiological saline
Concentration / amount:
intradermal induction phase: 1%
cutaneous induction phase: 25%
challenge phase: 10%
No. of animals per dose:
control group: 10 animals (5 Males + 5 Females)
treated group: 20 animals (10 Males + 10 Females)
Details on study design:
RANGE FINDING TESTS:
Determination of the Minimum Irritant Concentration by intradermal route at increasing concentrations (1%, 10%, 25%). Result: MIC=1%
Determination of the Minimum Irritant Concentration (MIC) and the Maximal Non Irritant Concentration (MNIC) by cutaneous route at increasing concentrations (5%, 10%, 25%, 50%, 75%, 100%). Result: MIC= 25%, MNIC=10%.


MAIN STUDY
A. INDUCTION EXPOSURE

Intradermal induction D1
3injections on the scapular area:
. 0.1mL of Freund's complete adjuvant 50% in 0.9% NaCl
. 0.1mL of the test item 0.1% in water (treated group) or vehicle (control group)
. 0.1mL of a mixture 50/50 (V/V) of Freund complete adjuvant 50% in 0.9% NaCl and vehicle (for control group) or test item 1% in vehicle (for treated group)

Cutaneous induction D8
. On day 7, the irritation created with the application of sodium Laurylsulfate 10% in vaseline.
. On day 8, occlusive application on the scapular area of 0.5mL of the test item 25% (for treated group) or vehicle (for control group) for 48hours.


B. CHALLENGE EXPOSURE D22
On day 22, 24-hour occlusive application on the scapular area of 0.5mL of the test item 10% on the right flank and 0.5mL of the vehicle on the left flank.
Reactions are evaluated 24 and 48 hours after removal of the dressing.
Positive control substance(s):
yes
Remarks:
Dinitro 2,4 Chlorobenzene: Positive result in recent study (July 1993- CIT/Study No. 10829 TPG) on 5 females. Induction: test substance injected intradermally 0.05% (d1) and applied cutaneously 0.5% (d8) concentration. Challenge: 0,1% r flank 0.5% l flank
Positive control substance(s):
other: Dinitro 2,4 chlorobenzene
Statistics:
no
Positive control results:
Positive skin sensitization reactions in 5/5 female Guinea pigs (July 1993- CIT/Study No. 10829 TPG).
Reading:
1st reading
Hours after challenge:
24
Group:
negative control
Dose level:
0
No. with + reactions:
0
Total no. in group:
10
Clinical observations:
No erythema/oedema
Remarks on result:
other: Reading: 1st reading. . Hours after challenge: 24.0. Group: negative control. Dose level: 0. No with. + reactions: 0.0. Total no. in groups: 10.0. Clinical observations: No erythema/oedema.
Reading:
2nd reading
Hours after challenge:
48
Group:
negative control
Dose level:
0
No. with + reactions:
0
Total no. in group:
10
Clinical observations:
No erythema/oedema
Remarks on result:
other: Reading: 2nd reading. . Hours after challenge: 48.0. Group: negative control. Dose level: 0. No with. + reactions: 0.0. Total no. in groups: 10.0. Clinical observations: No erythema/oedema.
Reading:
1st reading
Hours after challenge:
24
Group:
test chemical
Dose level:
10%
No. with + reactions:
6
Total no. in group:
19
Clinical observations:
well defined erythema/no oedema
Remarks on result:
other: Reading: 1st reading. . Hours after challenge: 24.0. Group: test group. Dose level: 10%. No with. + reactions: 6.0. Total no. in groups: 19.0. Clinical observations: well defined erythema/no oedema.
Reading:
2nd reading
Hours after challenge:
48
Group:
test chemical
Dose level:
10%
No. with + reactions:
3
Total no. in group:
19
Clinical observations:
well defined erythema/no oedema
Remarks on result:
other: Reading: 2nd reading. . Hours after challenge: 48.0. Group: test group. Dose level: 10%. No with. + reactions: 3.0. Total no. in groups: 19.0. Clinical observations: well defined erythema/no oedema.

Group

Sex

Animal

24h

48h

Erythema

Oedema

Erythema

Oedema

RF

LF

RF

LF

RF

LF

RF

LF

Control

M

21

0

0

0

0

0

0

0

0

22

0

0

0

0

0

0

0

0

23

0

0

0

0

0

0

0

0

24

0

0

0

0

0

0

0

0

25

0

0

0

0

0

0

0

0

 

Control

F

36

0

0

0

0

0

0

0

0

37

0

0

0

0

0

0

0

0

38

0

0

0

0

0

0

0

0

39

0

0

0

0

0

0

0

0

40

0

0

0

0

0

0

0

0

 

Treated

M

26

0

2

0

0

0

2/S

0

0

27

0

1

0

0

0

0

0

0

28

0

0

0

0

0

0

0

0

29

0

2

0

0

0

2/S

0

0

30

0

0

0

0

0

0

0

0

31

0

2

0

0

0

1/S

0

0

32

0

0

0

0

0

0

0

0

33

0

0

0

0

0

0

0

0

34

0

1

0

0

0

1/S

0

0

35

0

1

0

0

0

1/S

0

0

 

Treated

F

41

0

1

0

0

0

1

0

0

42

0

0

0

0

0

0

0

0

43

0

0

0

0

0

0

0

0

44

0

1

0

0

0

1

0

0

45

0

0

0

0

0

0

0

0

46

-

-

-

-

-

-

-

-

47

0

1

0

0

0

1

0

0

48

0

2

0

0

0

1/S

0

0

49

0

2

0

0

0

1/S

0

0

50

0

3

0

0

0

3/S

0

0

 S=Skin dryness

Interpretation of results:
other: Sensitiser cat. 1B
Remarks:
Criteria used for interpretation of results: EU
Conclusions:
DIMETHYLDIPROPYLENETRIAMINE induced positive skin sensitization cutaneous reactions in 6/19 (32%) guinea pigs. The allergenicity level of the test substance was moderate (III) in guinea-pigs.
Executive summary:

The delayed contact hypersensivity of dimethyldipropylenetriamine (DMAPAPA) was evaluated in Guinea pigs according to OECD N°406 guideline (Magnusson and Kligman test). The induction phase has been realized both by intradermal route on day 1 (DMAPAPA 1% in vehicle) and by cutaneous route on day 8 (DMAPAPA 25%) in 2 groups of guinea pigs: 5 males and 5 females for control group and 10 males and 10 females for treated group. The challenge phase was realized on day 22 by cutaneous application of DMAPAPA 10%; the cutaneous reactions were scored 24 and 48 hours after the challenge phase. Only one female of the treated group died on day 9 but this death was not considered to be treatment-related. No cutaneous reaction was observed in the animals of the control group. In the treated group, inconclusive evidence of sensitisation skin reactions (very slight erythema: score of 1) were noted in 6/19 animals after 24 hours. Positive response characterised by a well defined and moderate erythema (scores of 2 and 3) were noted in 6/19 animals after 24 hours. In addition, a dryness of the skin was noted after 48 hours in 8/19 animals.

No oedema was noted. In conclusion, the allergenicity level of Dimethyldipropylenetriamine was moderate (III) in guinea pigs.

Endpoint conclusion
Endpoint conclusion:
adverse effect observed (sensitising)
Additional information:

The delayed contact hypersensivity of N'-(3-aminopropyl) -N, N-dimethylpropane-1,3-diamine (DMAPAPA) was evaluated in Guinea pigs according to OECD N°406 guideline (Magnusson and Kligman test) (Clouzeau, 1994). The induction phase has been realized both by intradermal route on day 1 (DMAPAPA 1% in vehicle) and by cutaneous route on day 8 (DMAPAPA 25%) in 2 groups of guinea pigs: 5 males and 5 females for control group and 10 males and 10 females for treated group. The challenge phase was realized on day 22 by cutaneous application of DMAPAPA 10%; the cutaneous reactions were scored 24 and 48 hours after the challenge phase. Only one female of the treated group died on day 9 but this death was not considered to be treatment-related. No cutaneous reaction was observed in the animals of the control group. In the treated group, inconclusive evidence of sensitisation skin reactions (very slight erythema: score of 1) were noted in 6/19 animals after 24 hours. Positive response characterised by a well defined and moderate erythema (scores of 2 and 3) were noted in 6/19 animals after 24 hours. In addition, a dryness of the skin was noted after 48 hours in 8/19 animals. No oedema was noted. In conclusion, the allergenicity level of N'-(3-aminopropyl) -N, N-dimethylpropane-1,3-diamine was moderate (III) in guinea pigs.


Migrated from Short description of key information:
N'-(3-aminopropyl) -N, N-dimethylpropane-1,3-diamine induced skin sensitization cutaneous reactions in 6/19 (32%) guinea pigs. The allergenicity level of the test substance was moderate (III) in guinea-pigs.

Justification for selection of skin sensitisation endpoint:
Key study

Respiratory sensitisation

Endpoint conclusion
Endpoint conclusion:
no study available

Justification for classification or non-classification

Skin sensitization:

In a test performed following theGPMT's method, 32% of the guinea pigs reacted to an induction concentration of 1% N'-(3-aminopropyl) -N, N-dimethylpropane-1,3-diamine. On the basis of this study and in accordance with Regulation (EC) No 1272/2008, N'-(3-aminopropyl) -N, N-dimethylpropane-1,3-diamine was classified as skin sensitizer category 1B (Hazard statement H317; May cause an allergic skin reaction) and in accordance with Annex VI of Commission Directive 2001/59/EC, N'-(3-aminopropyl) -N, N-dimethylpropane-1,3-diamine was classified as irritant with the symbol Xi and the phrase R43 ‘May cause sensitisation by skin contact’.